What qualifies as “robust” when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation about those new Alzheimer’s disease results from Biogen and Eisai that, while ostensibly positive, have left many people scratching their heads. Then we’re joined by health care venture capitalist Lisa Suennen, who explains why there’s so much money flowing into digital health — and why some of it might as well be set on fire. And finally we’ll mark the end of an era at Gilead and speculate baselessly about who’s going to lead the company in the future.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy